Whether it’s Greenland, Ukraine, West Africa or East Asia, rare earths are an element of the global geopolitical competition ...

Journal of Nuclear Medicine January 2025, jnumed.124.268695; DOI: https://doi.org/10.2967/jnumed.124.268695 ...

(the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based ...

In recent years, traditional surgery, chemotherapy, and radiotherapy alone may fail to acquire satisfactory effects for patients. However, radiotherapy combined with immunotherapy will enhance the ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Among them, immunotherapy-based on HPV is very important. From current studies, we can see there are many kinds of immunotherapeutical methods or immunotherapy-like methods based on HPV studied in ...

Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New ...

Y-mAbs Therapeutics has undergone a significant transformation, restructuring its operations to concentrate on radioimmunotherapy. This strategic shift has placed the company at the forefront of ...

Service Unit for Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany ...